Petr Neužil, Angel Ferrero de Loma-Osorio, Ángel Martínez Brotons, Lourdes Bondanza Saavedra, Davide A Mei, Petr Moučka, Steffen Uffenorde, Jaime Vieira Ruiz, Giuseppe Boriani
{"title":"三种心脏消融技术治疗阵发性心房颤动的成本-后果分析。","authors":"Petr Neužil, Angel Ferrero de Loma-Osorio, Ángel Martínez Brotons, Lourdes Bondanza Saavedra, Davide A Mei, Petr Moučka, Steffen Uffenorde, Jaime Vieira Ruiz, Giuseppe Boriani","doi":"10.1080/13696998.2025.2575460","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>The rapid evolution of catheter ablation technologies has introduced variability in clinical outcomes, procedural efficiency, and costs. This study aimed to evaluate the economic costs and clinical outcomes associated with radiofrequency ablation (RFA), cryoablation (CRYO), and pulsed field ablation (PFA) for the treatment of paroxysmal atrial fibrillation (AF).</p><p><strong>Methods: </strong>A cost-consequence analytical model was developed to assess the economic impact and clinical outcomes of three treatment alternatives for adult patients with paroxysmal AF, from the hospital's perspective, in the short (index hospitalization) and medium-term (1 year). Real-world data were collected across three European specialty centers (Czech Republic, Italy, and Spain). The collected data captured procedural durations (including pre-procedural, skin-to-skin, and post-procedural phases), resource consumption, and staff workload. Costs were retrieved from institutional economic databases and published cost repositories. Costs were expressed in Euro (2025). Medium-term outcomes (complications, reinterventions, hospitalizations, cardioversions) were sourced from literature.</p><p><strong>Results: </strong>A total of <i>N</i> = 270 patients were included in the analysis. PFA was associated with consistency and predictable procedure duration compared to the other treatment alternatives. This efficiency may support increased capacity within the healthcare systems. PFA demonstrated cost saving of 10% compared to CRYO and 22% compared to RFA procedures, primarily driven by procedure time. Additionally, PFA showed a cost per responder of €2,406, versus €2,873 for CRYO (+19%) and €3,436 for RFA (+43%), reflecting both lower procedural costs and superior clinical outcomes.</p><p><strong>Conclusion: </strong>These findings suggest that PFA technology may offer economic and operational advantages, including more efficient resource utilization, reduced procedural complexity and consumables use, compared to traditional ablation modalities. However, variations in hospital clinical practices may limit the generalizability of results.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"1826-1839"},"PeriodicalIF":3.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost-consequence analysis of three cardiac ablation technologies in paroxysmal atrial fibrillation.\",\"authors\":\"Petr Neužil, Angel Ferrero de Loma-Osorio, Ángel Martínez Brotons, Lourdes Bondanza Saavedra, Davide A Mei, Petr Moučka, Steffen Uffenorde, Jaime Vieira Ruiz, Giuseppe Boriani\",\"doi\":\"10.1080/13696998.2025.2575460\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aim: </strong>The rapid evolution of catheter ablation technologies has introduced variability in clinical outcomes, procedural efficiency, and costs. This study aimed to evaluate the economic costs and clinical outcomes associated with radiofrequency ablation (RFA), cryoablation (CRYO), and pulsed field ablation (PFA) for the treatment of paroxysmal atrial fibrillation (AF).</p><p><strong>Methods: </strong>A cost-consequence analytical model was developed to assess the economic impact and clinical outcomes of three treatment alternatives for adult patients with paroxysmal AF, from the hospital's perspective, in the short (index hospitalization) and medium-term (1 year). Real-world data were collected across three European specialty centers (Czech Republic, Italy, and Spain). The collected data captured procedural durations (including pre-procedural, skin-to-skin, and post-procedural phases), resource consumption, and staff workload. Costs were retrieved from institutional economic databases and published cost repositories. Costs were expressed in Euro (2025). Medium-term outcomes (complications, reinterventions, hospitalizations, cardioversions) were sourced from literature.</p><p><strong>Results: </strong>A total of <i>N</i> = 270 patients were included in the analysis. PFA was associated with consistency and predictable procedure duration compared to the other treatment alternatives. This efficiency may support increased capacity within the healthcare systems. PFA demonstrated cost saving of 10% compared to CRYO and 22% compared to RFA procedures, primarily driven by procedure time. Additionally, PFA showed a cost per responder of €2,406, versus €2,873 for CRYO (+19%) and €3,436 for RFA (+43%), reflecting both lower procedural costs and superior clinical outcomes.</p><p><strong>Conclusion: </strong>These findings suggest that PFA technology may offer economic and operational advantages, including more efficient resource utilization, reduced procedural complexity and consumables use, compared to traditional ablation modalities. However, variations in hospital clinical practices may limit the generalizability of results.</p>\",\"PeriodicalId\":16229,\"journal\":{\"name\":\"Journal of Medical Economics\",\"volume\":\" \",\"pages\":\"1826-1839\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Economics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13696998.2025.2575460\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/10/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13696998.2025.2575460","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
Cost-consequence analysis of three cardiac ablation technologies in paroxysmal atrial fibrillation.
Background and aim: The rapid evolution of catheter ablation technologies has introduced variability in clinical outcomes, procedural efficiency, and costs. This study aimed to evaluate the economic costs and clinical outcomes associated with radiofrequency ablation (RFA), cryoablation (CRYO), and pulsed field ablation (PFA) for the treatment of paroxysmal atrial fibrillation (AF).
Methods: A cost-consequence analytical model was developed to assess the economic impact and clinical outcomes of three treatment alternatives for adult patients with paroxysmal AF, from the hospital's perspective, in the short (index hospitalization) and medium-term (1 year). Real-world data were collected across three European specialty centers (Czech Republic, Italy, and Spain). The collected data captured procedural durations (including pre-procedural, skin-to-skin, and post-procedural phases), resource consumption, and staff workload. Costs were retrieved from institutional economic databases and published cost repositories. Costs were expressed in Euro (2025). Medium-term outcomes (complications, reinterventions, hospitalizations, cardioversions) were sourced from literature.
Results: A total of N = 270 patients were included in the analysis. PFA was associated with consistency and predictable procedure duration compared to the other treatment alternatives. This efficiency may support increased capacity within the healthcare systems. PFA demonstrated cost saving of 10% compared to CRYO and 22% compared to RFA procedures, primarily driven by procedure time. Additionally, PFA showed a cost per responder of €2,406, versus €2,873 for CRYO (+19%) and €3,436 for RFA (+43%), reflecting both lower procedural costs and superior clinical outcomes.
Conclusion: These findings suggest that PFA technology may offer economic and operational advantages, including more efficient resource utilization, reduced procedural complexity and consumables use, compared to traditional ablation modalities. However, variations in hospital clinical practices may limit the generalizability of results.
期刊介绍:
Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication.
Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience